Tyra Biosciences, Inc., a clinical-stage biotechnology company, released its 10-K filing, detailing its financial performance and operational developments. The company, focused on precision medicines for oncology and genetically defined conditions, reported a net loss of $119.9 million for the year ended December 31, 2025, compared to a net loss of $86.5 million for the previous year. This increase in net loss is primarily attributed to escalating research and development expenses as the company advances its pipeline. As of December 31, 2025, Tyra Biosciences held $256.0 million in cash, cash equivalents, and marketable securities.
The company's research and development expenses totaled $102.9 million in 2025, up from $80.1 million in 2024. This increase was driven by a $17.0 million rise in external costs, particularly for the development of dabogratinib, including ongoing Phase 2 trials BEACH301 and SURF302, and start-up costs for SURF303. Additionally, there was a $3.4 million increase in development expenditures for SURF431. Internal costs, such as compensation and personnel expenses, also contributed to the increase, rising by $5.8 million. General and administrative expenses also increased to $29.8 million in 2025 from $24.1 million in 2024, primarily due to higher compensation and personnel expenses, including a $3.7 million increase in non-cash stock-based compensation costs.
Operationally, Tyra Biosciences is advancing its lead program, dabogratinib, through three Phase 2 trials: SURF303 for low-grade upper tract urothelial carcinoma (LG-UTUC), SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC), and BEACH301 for achondroplasia (ACH) in children. The first patient in the SURF303 study is anticipated to be dosed in 2026, and initial three-month complete response (CR) data from SURF302 is expected by the end of the first half of 2026. Initial data from the safety sentinel cohort of the BEACH301 study is expected in the second half of 2026. The company is also evaluating TYRA-430 in a Phase 1 trial for FGF19+ hepatocellular carcinoma (HCC) and TYRA-200 in a Phase 1 trial for FGFR2-driven intrahepatic cholangiocarcinoma (ICC) resistant to previous FGFR inhibitors. As of February 25, 2026, the company had 87 full-time employees, with 67 engaged in research and development.
Looking ahead, Tyra Biosciences anticipates continued investment in its pipeline and platform. The company believes its existing cash, cash equivalents, and marketable securities will fund operations through at least 2027. The company may also explore additional funding through equity offerings, debt financings, collaborations, licenses, and other strategic arrangements. The company's intellectual property portfolio, as of March 1, 2026, consisted of three granted U.S. patents, 11 pending U.S. provisional applications, 10 pending U.S. nonprovisional applications, 100 pending foreign patent applications, five granted foreign patents and 15 patent applications pursuant to the Patent Cooperation Treaty (PCT).
About Tyra Biosciences, Inc.
Tyra Biosciences is a clinical-stage biotech focused on developing precision medicines targeting FGFR biology for oncology and genetically defined conditions. Its in-house SNÅP platform enables rapid, selective drug design. Core programs include FGFR3 inhibitors for bladder cancer and skeletal disorders, FGFR2 inhibitors for cholangiocarcinoma, and FGFR4/3 inhibitors for hepatocellular carcinoma, aiming to address unmet medical needs with innovative, targeted therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.